The utility of neutrophil-to-lymphocyte ratio determined at initial diagnosis in predicting disease stage and discriminating between active and stable disease in patients with sarcoidosis: a cross-sectional study

Bekir, Sümeyye Alparslan; Sonkaya, Esin; Ozbaki, Fatma; Eroğlu, Selma Aydoğan; Sertçelik, Lale; Duman, Dildar; Kavas, Murat; Ağca, Meltem; Erdem, İpek; Özmen, İpek; Boga, Sibel; Hazar, Armagan; Sevim, Tülin; Türker, Hatice; Tunçay, Eylem; Güngör, Sinem; Karakurt, Zühal

doi:10.1080/00325481.2022.2082805

Cited by 2 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, it was shown that higher NLR values at the time of diagnosis were associated with a more advanced disease stage and an active clinical status in individuals with biopsy-proven sarcoidosis. A defined NLR cut-off value of ≥2.39 (with 72.0% sensitivity and 52.0% specificity) was established to effectively discriminate active from stable disease [118].…”

Section: Immune System and Sarcoidosismentioning

confidence: 99%

Phenotypes and Serum Biomarkers in Sarcoidosis

Della Zoppa,

Bertuccio,

Campo

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Sarcoidosis is a multisystem disease, which is diagnosed on a compatible clinical presentation, non-necrotizing granulomatous inflammation in one or more tissue samples, and exclusion of alternative causes of granulomatous disease. Considering its heterogeneity, numerous aspects of the disease remain to be elucidated. In this context, the identification and integration of biomarkers may hold significance in clinical practice, aiding in appropriate selection of patients for targeted clinical trials. This work aims to discuss and analyze how validated biomarkers are currently integrated in disease category definitions. Future studies are mandatory to unravel the diverse contributions of genetics, socioeconomic status, environmental exposures, and other sociodemographic variables to disease severity and phenotypic presentation. Furthermore, the implementation of transcriptomics, multidisciplinary approaches, and consideration of patients’ perspectives, reporting innovative insights, could be pivotal for a better understanding of disease pathogenesis and the optimization of clinical assistance.

show abstract

Section: Immune System and Sarcoidosismentioning

confidence: 99%

Phenotypes and Serum Biomarkers in Sarcoidosis

Della Zoppa,

Bertuccio,

Campo

et al. 2024

Diagnostics

View full text Add to dashboard Cite

show abstract

“…On the contrary, Patterson and co-workers found a higher level of IL-5 and altered levels of IL-7 and GM-CSF in pulmonary fibrosis, supporting the transition hypothesis [ 65 ]. Recently, among 465 patients with biopsy-proven sarcoidosis, it has been shown the utility of neutrophil–lymphocyte ratio (NLR) in predicting advanced disease stage and discriminating between active and stable disease [ 66 ]. However further studies are needed to understand the role of the Th1/Th2 axis in developing fibrosis in patients with pulmonary sarcoidosis.…”

Section: T Cellsmentioning

confidence: 99%

Molecular Mechanism in the Development of Pulmonary Fibrosis in Patients with Sarcoidosis

Cocconcelli

Bernardinello

Castelli

et al. 2023

IJMS

View full text Add to dashboard Cite

Sarcoidosis is a multisystemic disease of unknown etiology characterized by the formation of granulomas in various organs, especially lung and mediastinal hilar lymph nodes. The clinical course and manifestations are unpredictable: spontaneous remission can occur in approximately two thirds of patients; up to 20% of patients have chronic course of the lung disease (called advanced pulmonary sarcoidosis, APS) resulting in progressive loss of lung function, sometimes life-threatening that can lead to respiratory failure and death. The immunopathology mechanism leading from granuloma formation to the fibrosis in APS still remains elusive. Recent studies have provided new insights into the genetic factors and immune components involved in the clinical manifestation of the disease. In this review we aim to summarize the clinical-prognostic characteristics and molecular pathways which are believed to be associated with the development of APS.

show abstract

The utility of neutrophil-to-lymphocyte ratio determined at initial diagnosis in predicting disease stage and discriminating between active and stable disease in patients with sarcoidosis: a cross-sectional study

Abstract: The utility of NLR determined at initial diagnosis in predicting disease stage and discriminating between active and stable disease in patients with sarcoidosis : Cross-sectional study.

Cited by 2 publications

References 26 publications

Phenotypes and Serum Biomarkers in Sarcoidosis

Phenotypes and Serum Biomarkers in Sarcoidosis

Molecular Mechanism in the Development of Pulmonary Fibrosis in Patients with Sarcoidosis

Contact Info

Product

Resources

About